Market capitalization | €308.54m |
Enterprise Value | €348.39m |
P/E (TTM) P/E ratio | 16.29 |
EV/FCF (TTM) EV/FCF | 16.58 |
EV/Sales (TTM) EV/Sales | 2.93 |
P/S ratio (TTM) P/S ratio | 2.60 |
P/B ratio (TTM) P/B ratio | 9.65 |
Dividend yield | 1.90% |
Last dividend (FY25) | €0.51 |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
1 Analyst has issued a forecast Pharmasgp Holding:
1 Analyst has issued a forecast Pharmasgp Holding:
Dec '24 |
+/-
%
|
||
Revenue | 119 119 |
18%
18%
|
|
Gross Profit | 91 91 |
21%
21%
|
|
EBITDA | 37 37 |
9%
9%
|
EBIT (Operating Income) EBIT | 28 28 |
13%
13%
|
Net Profit | 20 20 |
19%
19%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PharmaSGP Holding SE engages in the manufacture of non-chemical, over-the-counter pharmaceutical products. Its product brands include RubaXX, Restaxil, FULMINAN, DESEO, Neradin, and TAUMEA. The company is headquartered in Gräfelfing, Germany.
Head office | Germany |
CEO | Peter Gerckens |
Employees | 91 |
Founded | 2012 |
Website | www.pharmasgp.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.